Need professional-grade analysis? Visit stockanalysis.com
$333.71M
135.00
156
N/A
Delcath Systems Inc (DCTH) trades on United States in USD. The company is classified in the Healthcare sector under the Medical Devices industry. The stock currently trades at $10.66, down 1.84% from the previous close.
Over the past year, DCTH has traded between a low of $8.19 and a high of $18.10. The stock has lost 10.9% over this period. It is currently 41.1% below its 52-week high.
Delcath Systems Inc has a market capitalization of $333.71M, with a price-to-earnings ratio of 135.00.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Side-by-side comparison against top Healthcare peers.